MedTrace Logo

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NCT06353646 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-02-13

No results posted yet for this study

Summary

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.

Conditions

Interventions

BIOLOGICAL

XH001

XH001 will be administered 12 weeks post-tumor resection (+/- 2 weeks)

DRUG

Ipilimumab Injection

Ipilimumab will be administered 12 weeks post-tumor resection (+/- 2 weeks)

DRUG

Sintilimab injection

Sintilimab will be administered 12 weeks post-tumor resection (+/- 2 weeks)

DRUG

Chemotherapy

gemcitabine + capecitabine

Sponsors & Collaborators

  • NeoCura

    collaborator INDUSTRY

  • Wu Wenming

    lead OTHER

Principal Investigators

  • Wenming WU, Prof. · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-12
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06353646 on ClinicalTrials.gov